China SXT raises $12M in registered direct offering

What's the deal? China SXT Pharmaceuticals Inc.Dealroom has a profile for this one. Try Dealroom → (NASDAQ: SXTC) has entered into a definitive agreement with institutional investors for a registered direct offering expected to raise roughly $12 million in gross proceeds. The Taizhou-based company will sell 8,000,000 Class A ordinary shares, or pre-funded warrants in lieu, at $1.50 each. The offering is expected to close on or about October 9, 2026.

What else is in it? Investors will also receive 8,000,000 warrants with a $1.50 exercise price, immediately exercisable and running for one year. Each warrant carries a zero cash exercise option allowing the holder to acquire up to nine Class A shares.

Who's involved? Univest Securities, LLCDealroom has a profile for this one. Try Dealroom → is acting as sole placement agent. The deal is being made under a shelf registration statement on Form F-3 that became effective on December 1, 2025.

What's the endgame? China SXT, founded in 2005, develops and sells traditional Chinese medicine pieces — processed medicine ready for use. Investors hold an additional right to buy up to $12 million more in securities on the same terms during the 30 days after closing.

What could go wrong? The warrant structure and zero cash exercise option could meaningfully expand the share count, diluting existing holders if those rights are exercised. The offering also remains subject to customary closing conditions.

The signal: For a small-cap pharma trading at $1.50 a share, tapping an effective shelf registration for a quick equity raise is a familiar move to shore up capital. The built-in follow-on right suggests the company is leaving room to pull in more if demand holds.

Read more: prnewswire.com

Image credit: jepoirrier